Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 13;15(1):227-244.
doi: 10.1158/2159-8290.CD-24-0573.

Cancer Prevalence across Vertebrates

Affiliations

Cancer Prevalence across Vertebrates

Zachary T Compton et al. Cancer Discov. .

Abstract

Cancer is pervasive across multicellular species, but what explains the differences in cancer prevalence across species? Using 16,049 necropsy records for 292 species spanning three clades of tetrapods (amphibians, sauropsids, and mammals), we found that neoplasia and malignancy prevalence increases with adult mass (contrary to Peto's paradox) and somatic mutation rate but decreases with gestation time. The relationship between adult mass and malignancy prevalence was only apparent when we controlled for gestation time. Evolution of cancer susceptibility appears to have undergone sudden shifts followed by stabilizing selection. Outliers for neoplasia prevalence include the common porpoise (<1.3%), the Rodrigues fruit bat (<1.6%), the black-footed penguin (<0.4%), ferrets (63%), and opossums (35%). Discovering why some species have particularly high or low levels of cancer may lead to a better understanding of cancer syndromes and novel strategies for the management and prevention of cancer. Significance: Evolution has discovered mechanisms for suppressing cancer in a wide variety of species. By analyzing veterinary necropsy records, we can identify species with exceptionally high or low cancer prevalence. Discovering the mechanisms of cancer susceptibility and resistance may help improve cancer prevention and explain cancer syndromes. See related commentary by Metzger, p. 14.

PubMed Disclaimer

Conflict of interest statement

Z.T. Compton reports grants from NIH during the conduct of the study. W. Mellon reports grants from National Institutes of Health during the conduct of the study. D. Mallo reports grants from NIH and DOD during the conduct of the study; personal fees from Wellcome Trust and University of California, Santa Cruz outside the submitted work. S.E. Kapsetaki reports personal fees from Arizona State University during the conduct of the study. M. Wilmot reports grants from NIH during the conduct of the study. R. Kennington reports grants from NIH during the conduct of the study. K. Noble reports grants from NIH during the conduct of the study. B. Martins reports grants from National Institutes of Health during the conduct of the study. S. Aksoy reports grants from National Institutes of Health during the conduct of the study. A. Zehnder reports personal fees from Fauna Bio outside the submitted work. T.A. Graham reports personal fees from Genentech outside the submitted work; in addition, T.A. Graham has a patent for GB2305655.9 pending and a patent for GB2317139.0 pending. J.D. Schiffman reports personal fees and non-financial support from Peel Therapeutics, Inc. outside the submitted work. L.M. Abegglen reports grants from NIH and Primary Children’s Hospital Foundation during the conduct of the study; personal fees from Peel Therapeutics outside the submitted work. A.M. Boddy reports Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U54CA217376. No disclosures were reported by the other authors.

Figures

Figure 1.
Figure 1.
A, Vertebrate species represented in our database overlaid upon the entire vertebrate phylogeny. Neoplasia and malignancy prevalence across (B) mammals, (C) sauropsids (Aves, Squamata, Testudines, and Crocodylia), and (D) amphibians. Silhouetted species indicate that zero neoplasms were reported in our data.
Figure 2.
Figure 2.
Distributions of (A) neoplasia (Kruskal–Wallis test: P = 2.906 × 10−12) and (B) malignancy (Kruskal–Wallis test: P = 6.519 × 10−11) prevalences are different across four clades, Amphibia, Mammalia, Aves, and Squamata. Dots show the estimated species neoplasia prevalence and bars show the median for the clade. Neoplasia and malignancy prevalence for species were calculated by the proportion of the reported lesions among the total number of necropsies for that species. N indicates the number of necropsies in each clade.
Figure 3.
Figure 3.
Significant life history factors associated with neoplasia and malignancy prevalence. A, Larger organisms have a higher neoplasia prevalence than smaller organisms (2.1% neoplasia per Log10g adult body mass, P = 0.007, R2 = 0.26, λ = 0.46). B, Larger organisms may have a higher malignancy prevalence than smaller organisms but it is not statistically significant when we do not control for gestation time (0.65% malignancies per Log10g adult body mass, P = 0.29, R2 = 0.28, λ = 0.61). C, Longer lived organisms have more neoplasia (0.01% neoplasia per Log10 month lifespan, P = 0.02, R2 = 0.19, λ = 0.34). D, Longer lived organisms also have more malignancies (3.3% malignancies per Log10 month lifespan, P = 0.17, R2 = 0.21, λ = 0.47). E, Organisms with longer gestation times have a lower neoplasia prevalence (−5.30% neoplasia per Log10 months, P = 0.10, R2 = 0.11, λ = 0.34). F, Organisms with longer gestation times have a lower malignancy prevalence (−5.65% malignancies per Log10 months, P = 0.02, R2 = 0.16, λ = 0.41). When controlling for adult body mass, organisms with longer gestation times also have fewer neoplasms at death (−15.8% neoplasia per Log10 months gestation, P = 0.0002).
Figure 4.
Figure 4.
A, Cell cycle arrest as measured by % cell growth over time (AUC) relative to untreated at 10 Gy of radiation (plotted and analyzed on a Log10 scale) as a predictor of neoplasia prevalence in species’ fibroblast cell lines. (0.31% neoplasia per % cell growth over time, P = 0.19, R2 = 0.32, λ = 0.86). B, Log10 mean mutation rate as a predictor of neoplasia prevalence (47.26% per single base substitution per genome per year, P = 0.0059, R2 = 0.63, λ = 1.00).
Figure 5.
Figure 5.
The density distribution of ages at death in animals with neoplasia vs. non-neoplasia, adjusted for each species’ lifespan as specified in PanTHERIA. While the distributions of ages at death are different between necropsies showing neoplasia vs. those that do not (two-sample Kolmogorov–Smirnov test: (A and B) Mammals: D = 0.11, P = 1.81 × 10−6; (C and D) Sauropsids: D = 0.18; P = 4.48 × 10−8; (E and F) Amphibians: D = 0.5, P = 0.011); we found few neoplasms that could be explained by an organism living an extraordinarily long time in captivity, except in amphibians. We only had seven amphibians with a malignancy at death, one of which lived past its normal lifespan, so the shape of the distribution in F is noisy.
Figure 6.
Figure 6.
Cladogram depiction of cancer prevalence within (A) Mammals, (B) Sauropsids, and (C) Amphibians. Cladograms with the species labels at each tip can be found in Supplementary Fig. S72. Heat map coloration indicates relative prevalence of cancer within each branch, illustrating the diversity of neoplastic disease among closely related species. The scale is the same for each panel so that the differences between the clades are apparent.

Update of

  • Cancer Prevalence Across Vertebrates.
    Compton ZT, Mellon W, Harris V, Rupp S, Mallo D, Kapsetaki S, Wilmot M, Kennington R, Noble K, Baciu C, Ramirez L, Peraza A, Martins B, Sudhakar S, Aksoy S, Furukawa G, Vincze O, Giraudeau MT, Duke E, Spiro S, Flach E, Davidson H, Li C, Zehnder A, Graham TA, Troan B, Harrison T, Tollis M, Schiffman J, Aktipis A, Abegglen L, Maley C, Boddy A. Compton ZT, et al. bioRxiv [Preprint]. 2024 Apr 22:2023.02.15.527881. doi: 10.1101/2023.02.15.527881. bioRxiv. 2024. Update in: Cancer Discov. 2025 Jan 13;15(1):227-244. doi: 10.1158/2159-8290.CD-24-0573. PMID: 36824942 Free PMC article. Updated. Preprint.
  • Cancer Prevalence Across Vertebrates.
    Compton ZT, Harris V, Mellon W, Rupp S, Mallo D, Kapsetaki SE, Wilmot M, Kennington R, Noble K, Baciu C, Ramirez L, Peraza A, Martins B, Sudhakar S, Aksoy S, Furukawa G, Vincze O, Giraudeau M, Duke EG, Spiro S, Flach E, Davidson H, Zehnder A, Graham TA, Troan B, Harrison TM, Tollis M, Schiffman JD, Aktipis A, Abegglen LM, Maley CC, Boddy AM. Compton ZT, et al. Res Sq [Preprint]. 2023 Jul 6:rs.3.rs-3117313. doi: 10.21203/rs.3.rs-3117313/v1. Res Sq. 2023. Update in: Cancer Discov. 2025 Jan 13;15(1):227-244. doi: 10.1158/2159-8290.CD-24-0573. PMID: 37461608 Free PMC article. Updated. Preprint.

References

    1. Aktipis CA, Boddy AM, Jansen G, Hibner U, Hochberg ME, Maley CC, et al. Cancer across the tree of life: cooperation and cheating in multicellularity. Philos Trans R Soc Lond B Biol Sci 2015;370:20140219. - PMC - PubMed
    1. Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA 2021;325:1829–30. - PMC - PubMed
    1. Daignan-Fornier B, Laporte D, Sagot I. Quiescence through the prism of evolution. Front Cell Dev Biol 2021;9:745069. - PMC - PubMed
    1. Kirk DL. A twelve-step program for evolving multicellularity and a division of labor. Bioessays 2005;27:299–310. - PubMed
    1. Nedelcu AM. The evolution of multicellularity and cancer: views and paradigms. Biochem Soc Trans 2020;48:1505–18. - PubMed